Turbine’s Post

In recent years, #drug discovery has undergone a transformative evolution marked by technological advancements and innovative methodologies. This #eBook from Technology Networks explores drug discovery, design and development, highlighting challenges and solutions, successes, various modalities and approaches. https://lnkd.in/eeCMR--U

🎉 **Exciting News from Disruptive Pharma!** 🎉 We're thrilled to announce that our beamtime proposal at MAX IV has been accepted! This gives us an incredible opportunity to delve into the physical state and spatial distribution of active pharmaceutical ingredients (APIs) loaded in mesoporous magnesium carbonate (MMC). Our team, consisting of skilled scientists from both Disruptive Pharma and RISE Research Institutes of Sweden will conduct a cutting-edge scanning X-ray diffraction (XRD) experiment at the NanoMAX beamline at MAX IV. Utilizing a nano-focused X-ray beam, we aim to gain unparalleled insights into the physical state and spatial distribution of APIs within MMC particles. This detailed understanding will significantly contribute to refining drug delivery systems and enhancing therapeutic efficacy. Stay tuned for updates as we embark on this exciting journey to revolutionize drug delivery systems! Special thanks to: Petru Niga,Simone Sala, Jenny Rissler, Jonas Fagerberg #DrugDelivery #Beamtime #MAXIV #NanoMAX #XRayDiffraction #InnovationInPharma #Collaboration #RISE #Vinnova #bioavailability

Agilent is hosting an Immunotherapy Symposium, followed by a “Live” Demo reception on March 26– in Cambridge from 1pm-6.30pm EST. Seats are limited— register today! Meet industry experts and explore solutions in real-time, impedance-based analysis of cell function, real time metabolism, cell imaging and microscopy, flow cytometers, and more! Learn about our Cell Analysis applications and workflows, get your Software questions answered, and learn how you can get personalized training on YOUR DATA! Heather Sampson Lustig Suzie Shoup Sabrina Hawthorne Jenny (Zhe) Zhang Craig Abrahams Natalia Romero Leyna Z. Diane Kambach, Ph.D. Suzanne Armitstead Melanie Herscovitch Cliff Leavitt Jason Field Daniel Disher Lauren Dostillio Peggy Taphorn Leena Paul, Ph.D #seahorse #immunology #cellandgenetherapy #flowcytometry #metabolism #metabolomics #celltherapymanufacturing #immunooncology #immunotherapy #microscopy #confocal #imaging

🚨AACR ATTENDEES🚨 With a multitude of large pharma beefing up their existing ADC pipelines due to confidence with the technology, de-risked development, and potentially longer market exclusivity; these drugs will be key growth drivers for their businesses, making it imperative to invest in a real-world data strategy to support your ADC development. By leveraging TEMPUS’ pre/post ADC treated real-world data, we’re uniquely positioned to support the following areas you must prioritize: 1. Building a combination strategy w/ ICI’s (avg PTRS >50% relative to monotherapy ADC trials) 2. In the post-progression setting, better understand what’s driving resistance to specific ADCs in specific tumor types (targeted vs payload) 3. Identify “pan-tumor potential” by understanding where to play - EGFR, TROP2, and Nectin-4 have ph 2 pan-tumor studies active, and other targets are showing similar potential Stop by our booth and lets chat!

Meet Dr JIA LU: Principal Scientist in the Target Discovery Team. In our latest Meet the Team blog, we spoke with Jia to learn more about the challenges associated with the development of new molecular glue degraders and how GlueSEEKER represents a unique opportunity to design and evaluate novel protein-protein interactions.   Jia also shared updates on our internal TPD-focused programs and partnerships with industry-leading pharma companies, where we are deploying our SITESEEKER platform across a range of therapeutic areas. Find the full interview here: https://rb.gy/6w34mg #MolecularGlues #TPD #Drug Discovery

In this recently published article, Dr. Julie Suman of Aptar Pharma and Conor Ruzycki of Lovelace Biomedical discuss the role of preclinical studies when investigating nasal delivery systems, and how these can help overcome the challenges associated with pulmonary doses. Read the full article here: https://ow.ly/zMbw50Ulywu #NasalDrugDelivery #PulmonaryDrugDelivery #InhalationDrugDelivery #Preclinical

What's the most impactful or misleading advice you've encountered in your career? Join us for this Pharma's Almanac roundtable, where a panel of industry experts delve into the conventional wisdom they believe is outdated, misguided, or simply incorrect. Read the full roundtable here: https://lnkd.in/eTsQ4qj9 Our roundtable features contributors from Vectron Biosolutions AS, Alconox Inc., PPD, Dynamk Capital, Mikart, LLC, Tanvex CDMO, Scorpius BioManufacturing, Inc., Envisagenics, Qualtrics, Astrea Bioseparations, Charles River Laboratories, Epocrates Inc, eClinical Solutions, Rentschler Biopharma, Be The Match BioTherapies, MMIT (Managed Markets Insight & Technology), Catalent Pharma Solutions, LabVantage Solutions, Inc, Personalis, Inc., Rune Labs, Mission Bio, VintaBio, BioCina, Center for Breakthrough Medicines, Alto Neuroscience, Elixirgen Therapeutics, Inc., Seer, Karius, Opentrons Labworks Inc., Rani Therapeutics, OM1, Inc., BIOSENIC S.A., eXmoor Pharma, BioBridge Global, Terumo Blood and Cell Technologies, TrakCel, ScaleReady, Ori Biotech... (cont) #Biopharma #Insights #Pharma #Roundtable

🚀 Big Pharma Sharma: Key Insights on Lyell Immunopharma’s LYL797 Data This week’s edition of Big Pharma Sharma delves into Lyell Immunopharma recent data from its lead program, LYL797 (next-gen ROR1 CAR-T). As the company navigates early efficacy signals and significant safety concerns, crucial strategic decisions loom on the horizon. 🔬 Key Discussion Points: • Initial efficacy and safety data from LYL797 in TNBC and NSCLC • Emerging lung-related AEs prompting a rethink of dosing protocols • Potential implications for Lyell’s future strategy and pipeline expansion 🛤️ What lies ahead? Find out more in this week’s edition of Big Pharma Sharma. Don’t miss the full analysis and insider insights! Link to the full post in the comments. That’s it for this week’s edition. I’ll be on a break for the next couple of weeks, enjoying some vacation time over the 4th of July holiday. Stay tuned for more when I return!

🎙️Three biotech CMOs discuss how biotech CMOs can set their assets up for success before getting into the clinic, the key skills needed to bridge the scientific and clinical functions of the company and how to collaborate effectively with CSOs. Moderated by Dr Joseph Elassal, Ankyra Therapeutics, panelists include: • Dr Steven Katz, TriSalus Life Sciences • Dr Andrea Wang-Gillam, Jacobio Pharma Listen to the podcast here: https://lnkd.in/gp-CKn3b #CMOSummit360 #CMO #CSO #biotech #clinicalresearch #translationalscience

Published online: "COMPREHENSIVE TESTING PROVES DESIGN CONCEPT OF NOVEL AUTOINJECTOR PLATFORM". Read the full ONdrugDelivery article 👉 https://lnkd.in/e4VRBdrU "Farid Seddighi, Ph.D. of Gerresheimer and Sigrid Saaler-Reinhardt, Prof. Dr. and Daniel Primavessy of Midas Pharma discuss the critical importance of testing at an early stage of medical device development, presenting an overview of the results that confirm the technical performance and usability of the novel Gx Inbeneo® autoinjector. "